AUTHOR'S REPLY: Carter and Skoutakis have addressed the issue of what a "step forward" means to them. I would also like to add that during the development of low-molecular-weight heparins (LMWHs), significant advances were made in our knowledge of the mechanism of action, pharmacokinetics, and pharmacodynamics of unfractionated heparin. The issue of LMWHs being a step forward was not "missed," as Saltiel and Saya suggest. Not only am I in agreement with the statement made by Carter et al. in their review.' I believe that LMWHs as a class of antithrombotic agents is one of the most significant advances in antithrombotic therapy in the last 25-30 years.
With regard to the issue of economic foolhardiness, I can appreciate Saltiel and Saya's concern. As administrators of a pharmacy department, we are naturally attentive to the impact that the cost of any new drug has on the pharmacy budget. Some additional points must be considered in order to fully address the issue of cost containment. The pharmacokinetic profile of LMWHs allows for less frequent dosing than adjusted-dose Letters heparin. Also, prophylaxis with adjusted-dose heparin or warfarin requires monitoring activated partial thromboplastin times or prothrombin times that add considerable cost to these therapeutic modalities. The use of unfractionated heparin or warfarin is not free of adverse effects either. Prolonged hospital courses resulting from complications such as thrombocytopenia and bleeding must also be considered when evaluating costeffectiveness. Carter and Skoutakis also point out that many orthopedic surgeons do not use any antithrombotic prophylaxis, thus exposing postsurgical patients to the risk of developing deep-vein thrombosis or pulmonary embolism, again at what cost? This is a time of healthcare reform. As pharmacists we have an obligation to help control the escalating costs of healthcare. Does this mean simply providing the least expensive drug, or should we take a more global approach to providing quality care? Shouldn't we make the best use of each healthcare dollar through the reduction of adverse effects, decreased laboratory costs, and shortened hospital stays, even if this means the use of a more expensive drug? Table I is The Annals ofPharmacotherapy • 1994 June, Volume 28 • 811
